0000950170-24-007032.txt : 20240124
0000950170-24-007032.hdr.sgml : 20240124
20240124170005
ACCESSION NUMBER: 0000950170-24-007032
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240122
FILED AS OF DATE: 20240124
DATE AS OF CHANGE: 20240124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Savill Corrine
CENTRAL INDEX KEY: 0001837524
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 24557284
MAIL ADDRESS:
STREET 1: C/O CULLINAN ONCOLOGY, LLC
STREET 2: ONE MAIN STREET SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Oncology, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
ownership.xml
4
X0508
4
2024-01-22
0001789972
Cullinan Oncology, Inc.
CGEM
0001837524
Savill Corrine
C/O CULLINAN ONCOLOGY, INC.
ONE MAIN STREET, SUITE 1350
CAMBRIDGE
MA
02142
false
true
false
false
Chief Business Officer
true
Common Stock
2024-01-22
4
M
false
14559
4.3
A
184674
D
Common Stock
2024-01-22
4
S
false
14559
12.18
D
170115
D
Common Stock
2024-01-22
4
S
false
4125
12.02
D
165990
D
Common Stock
2024-01-23
4
M
false
21316
4.3
A
187306
D
Common Stock
2024-01-23
4
S
false
21316
12.46
D
165990
D
Stock Option (Right to Buy)
4.30
2024-01-22
4
M
false
14559
0.00
D
2030-10-28
Common Stock
14559
35313
D
Stock Option (Right to Buy)
4.30
2024-01-23
4
M
false
21316
0.00
D
2030-10-28
Common Stock
21316
13997
D
Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023.
/s/ Jacquelyn Sumer, Attorney-in-Fact
2024-01-24